From the initial cohort of 97 patients with polymerase chain reaction (PCR)–proven COVID-19 with acute olfactory disorders lasting for more than 7 days, 51 patients were followed up for a year, with subjective and objective olfactory assessment every 4 months, until normalization of objective olfactory test results. ENT indicates ear, nose, and throat.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Renaud M, Thibault C, Le Normand F, et al. Clinical Outcomes for Patients With Anosmia 1 Year After COVID-19 Diagnosis. JAMA Netw Open. 2021;4(6):e2115352. doi:10.1001/jamanetworkopen.2021.15352
Since the pandemic was declared in early 2020, COVID-19–related anosmia quickly emerged as a telltale sign of infection.1,2 However, the time course and reversibility of COVID-19–related olfactory disorders, which may persist and negatively affect patients’ lives, require further study. To clarify the clinical course and prognosis, we followed a cohort of patients with COVID-19–related anosmia for 1 year and performed repeated olfactory function evaluations for a subset of patients.
This cohort study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline. Participants provided written informed consent. The study was approved by the ethics committee of the University Hospitals of Strasbourg.
In April 2020, we published a study1 about a cohort of patients with polymerase chain reaction–proven COVID-19 with acute smell loss (lasting >7 days). Over the course of 1 year, at 4-month intervals, patients were asked to complete a survey, and their olfactory function was assessed by psychophysical testing (the threshold and identification tests; Sniffin’ Sticks Test; Burghardt).3 Hyposmic or anosmic patients were followed until objective olfactory recovery (normal results were defined as those at or above the 10th percentile). Data analysis was performed from June 2020 to March 2021.
We evaluated 97 patients (67 women [69.1%]; mean [SD] age, 38.8 [11.5] years) with acute smell loss beyond 7 days. Of these patients, 51 (52.6%) underwent both subjective and objective olfactory test, and 46 (47.4%) underwent subjective assessment alone (Figure). After subjective assessment at 4 months, 23 of 51 patients (45.1%) reported full recovery of olfaction, 27 of 51 patients (52.9%) reported partial recovery, and 1 of 51 patients (2.0%) reported no recovery. On psychophysical testing, 43 of 51 patients (84.3%) were objectively normosmic, including 19 of 27 (70.0%) who self-evaluated as only partially recovered (all patients who self-reported normal return of smell were corroborated with objective testing) (Table). The remaining 8 patients (15.7%) with persistent subjective or objective loss of smell were followed up at 8 months, and an additional 6 patients became normosmic on objective testing. At 8 months, objective olfactory assessment confirmed full recovery in 49 of 51 patients (96.1%). Two patients remained hyposmic at 1 year, with persistent abnormalities (1 with abnormal olfactory threshold and 1 with parosmia causing abnormal identification). Among those who underwent subjective assessment alone, 13 of 46 patients (28.2%) reported satisfactory recovery at 4 months (7 with total and 6 with partial recovery), and the remaining 33 patients (71.7%) did so by 12 months (32 with total and 14 with partial recovery).
More than 1 year into the pandemic, we describe the long-term prognosis for a cohort of patients with COVID-19–related anosmia, most of whom (96.1%) objectively recovered by 12 months. Our findings suggest that an additional 10% gain in recovery can be expected at 12 months, compared with studies with 6 months of follow-up that found only 85.9% of patients with recovery.4 This supports findings from fundamental animal research, involving both imaging studies and postmortem pathology, suggesting that COVID-19–related anosmia is likely due to peripheral inflammation.4
We also confirmed that discrepancies exist between self-assessed and objective testing, whereby participants tend to underappreciate the return of normosmia. This highlights the importance of applying both methods for postviral olfactory disorder evaluation.5 Discrepancies could be explained by qualitative disorders disrupting self-assessment (eg, parosmia) and/or limited capacity of olfactory tests to capture a complete return to function among individuals with higher baseline olfactory abilities.
The main limitation of our study was that only one-half of the cohort underwent objective olfactory testing. However, all participants were contacted at 12 months and almost all reported a subjective return of smell. It should also be noted that our cohort consisted mainly of women and younger patients (<50 years old), both of which are factors positively associated with full olfactory recovery.6
Persistent COVID-19–related anosmia has an excellent prognosis with nearly complete recovery at 1 year. As clinicians manage an increasing number of people with post-COVID syndrome, data on long-term outcomes are needed for informed prognostication and counseling.
Accepted for Publication: April 28, 2021.
Published: June 24, 2021. doi:10.1001/jamanetworkopen.2021.15352
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Renaud M et al. JAMA Network Open.
Corresponding Author: Marion Renaud, MD, Otorhinolaryngology Department, University Hospitals of Strasbourg, 1 Ave Moliere, 67200 Strasbourg, France (firstname.lastname@example.org).
Author Contributions: Drs Renaud and Venkatasamy had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Renaud, Debry, Venkatasamy.
Acquisition, analysis, or interpretation of data: Renaud, Thibault, Le Normand, Mcdonald, Gallix, Venkatasamy.
Drafting of the manuscript: Renaud, Venkatasamy.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Renaud, Venkatasamy.
Obtained funding: Venkatasamy.
Administrative, technical, or material support: Renaud, Thibault, Le Normand, Gallix.
Supervision: Renaud, Gallix, Debry, Venkatasamy.
Conflict of Interest Disclosures: None reported.
Funding/Support: This work was supported by French state funds managed within the Plan Investissements d’Avenir and by the Agence Nationale de la Recherche (grant No. ANR-10-IAHU-02).
Role of the Funder/Sponsor: The specific role of the funding organization was interpretation of data, review and approval of the manuscript, and decision to submit the manuscript for publication. The funder had no role in the design and conduct of the study; collection, management, and analysis of data; and preparation of the manuscript.
Create a personal account or sign in to: